Yet, the importance of IGF-1R signaling per se on health and aging beyond the mouse is mainly limited to human trials involving IGF-1R mAb treatment in cancer patients, where the goal is to substantially block IGF-1Rs, which can result in hyperglycemia and elevated hemoglobin A1c levels in some patients15. This evidence concerns the gene IGF1R and Hyperglycemia.